JP2023517736A5 - - Google Patents

Info

Publication number
JP2023517736A5
JP2023517736A5 JP2022555846A JP2022555846A JP2023517736A5 JP 2023517736 A5 JP2023517736 A5 JP 2023517736A5 JP 2022555846 A JP2022555846 A JP 2022555846A JP 2022555846 A JP2022555846 A JP 2022555846A JP 2023517736 A5 JP2023517736 A5 JP 2023517736A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
cancer
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022555846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022474 external-priority patent/WO2021188480A1/en
Publication of JP2023517736A publication Critical patent/JP2023517736A/ja
Publication of JP2023517736A5 publication Critical patent/JP2023517736A5/ja
Withdrawn legal-status Critical Current

Links

JP2022555846A 2020-03-16 2021-03-16 免疫調節剤 Withdrawn JP2023517736A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989940P 2020-03-16 2020-03-16
US62/989,940 2020-03-16
PCT/US2021/022474 WO2021188480A1 (en) 2020-03-16 2021-03-16 Immunomodulators

Publications (2)

Publication Number Publication Date
JP2023517736A JP2023517736A (ja) 2023-04-26
JP2023517736A5 true JP2023517736A5 (https=) 2024-03-26

Family

ID=75539903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555846A Withdrawn JP2023517736A (ja) 2020-03-16 2021-03-16 免疫調節剤

Country Status (6)

Country Link
US (1) US20230183292A1 (https=)
EP (1) EP4121442A1 (https=)
JP (1) JP2023517736A (https=)
KR (1) KR20220155332A (https=)
CN (1) CN115485288A (https=)
WO (1) WO2021188480A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022221284A2 (en) * 2021-04-12 2022-10-20 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
KR20230044603A (ko) * 2021-09-27 2023-04-04 (주) 테라베스트 약물 이합체를 포함하는 나노입자 및 이의 용도
WO2024149369A1 (zh) * 2023-01-13 2024-07-18 苏州慧疗生物医药科技有限公司 甾体化合物、制备方法及其脂质纳米颗粒、药物组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU2002211863A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
CZ2012326A3 (cs) * 2012-05-18 2013-10-30 Vysoká skola chemicko-technologická v Praze Konjugáty hydrazonu s kyselinou cholovou jako nová cytostatika
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) * 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
HRP20210644T8 (hr) * 2016-05-19 2021-06-25 Bristol-Myers Squibb Company Imunomodulatori za pet-snimanje
KR20220010535A (ko) * 2019-05-21 2022-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제

Similar Documents

Publication Publication Date Title
JP2023510737A5 (https=)
JP2023517736A5 (https=)
JP2023510736A5 (https=)
JP2016519062A5 (https=)
JP2019512478A5 (https=)
JP2023533938A5 (https=)
JP2020525429A5 (https=)
JP2020515574A5 (https=)
JP2017536344A5 (https=)
JP2018511590A5 (https=)
JP2016503414A5 (https=)
JP2013539795A5 (https=)
JP2013522292A5 (https=)
RU2528386C2 (ru) Новые производные пиримидина
JP2019534865A5 (https=)
JP2023503050A5 (https=)
HRP20192337T1 (hr) Makrociklični inhibitori pd-1/pd-l1 i cd80(b7-1)/pd-l1 protein/protein interakcija
RU2015126856A (ru) Дисульфидные маскированные пролекарственные композиции и способы
JP2012153722A5 (https=)
JP2017515901A5 (https=)
JP2010523670A5 (https=)
EP2688883A1 (en) Novel pyrimidine derivatives
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
JP2018521135A5 (https=)
JP2015051994A5 (https=)